ArticleBMC psychiatry2026
The association between inflammation biomarkers with mental and behavioral disorders due to use of tobacco: a cross-section and cohort study.
Article in BMC psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTobacco use was as an unhealthy lifestyle. But there were few studies about mental and behavioral disorders due to use of tobacco (MBDT). Inflammation played a role in several mental and behavioral disorders. Hence, this research investigated the association between inflammation biomarkers and MBDT.
methodsWe selected 10 inflammation biomarkers including lymphocyte (LYM), neutrophil (NEU), monocyte (MON), platelet (PLT), aggregate index of systemic inflammation (AISI), systemic inflammatory response index (SIRI), systemic immune-inflammatory index (SII), platelet-to-Lymphocyte ratio (PLR), lymphocyte-to-monocyte ratio (LMR) and neutrophil-to-lymphocyte ratio (NLR) to explore the association between inflammation biomarkers and MBDT in a cross-section study and a dynamic cohort study. To explore the dose-response relationship between inflammation biomarkers MBDT, the restricted cubic spline was performed. Besides, the stratified analyses and sensitive analyses were used to test the stability of results.
resultsAccording to results of cohort study, all inflammation biomarkers were significantly associated with the risk of MBDT. The changes in HRs (95%CI) for per SD increment of inflammation biomarkers were as follows: LYM: 1.46 (1.43–1.48); NEU: 1.53 (1.51–1.55); MON: 1.25 (1.23–1.27); PLT: 1.06 (1.04–1.08); AISI: 1.16 (1.14–1.18); SIRI: 1.17 (1.16–1.19); SII: 1.08 (1.06–1.09); LMR: 1.14 (1.12–1.15); NLR: 1.06 (1.05–1.08); PLR: 0.73 (0.72–0.75).
conclusionHigher LYM, NEU, MON, PLT, AISI, SIRI, NLR, LMR and SII may be associated with higher risk of MBDT, and higher PLR may be associated with lower risk of MBDT. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.